Restricted accessReview articleFirst published online 2025-10
Left atrial appendage occlusion in patients with atrial fibrillation and previous Intracranial Hemorrhage or Cerebral Amyloid Angiopathy: A systematic review and meta-analysis
Patients with atrial fibrillation (AF) on oral anticoagulation (OAC) who have a history of intracranial hemorrhage (ICrH) or cerebral amyloid angiopathy (CAA) have an elevated risk of ICrH recurrence. Left atrial appendage occlusion (LAAO) has emerged as a potential alternative to OAC for stroke prevention in high-bleeding-risk AF patients. Small observational studies suggest that LAAO may be safe and feasible in patients with ICrH, when using single or dual antiplatelet therapy or short-term OAC post-procedure, though data remain limited. This systematic review and meta-analysis aims to consolidate evidence on the safety and efficacy of LAAO in patients with prior ICrH or CAA.
Methods:
We conducted a systematic review and meta-analysis examining the safety and efficacy of LAAO in patients with non-valvular AF and prior ICrH and/or CAA. PubMed/MEDLINE and EMBASE (via Scopus) databases were systematically searched from inception until 29 February 2024. Eligible studies included randomized control trials, observational studies, and case series (⩾10 participants) reporting stroke events in patients with AF and previous history of ICrH and/or CAA undergoing LAAO. Pooled incidence rates (IRs) with corresponding 95% confidence intervals (CIs) were calculated for primary outcomes (post-procedural ischemic stroke and recurrent ICrH) and secondary outcomes.
Results:
Fourteen studies including 1235 patients met inclusion criteria. The pooled average follow-up period was 17.1 months. The pooled IRs for ischemic stroke, recurrent ICrH, and major hemorrhage were 2% (95% CI: 1–3%, I2 = 2%), 2% (95% CI: 0.4–3%, I2 = 45%) and 3% (95% CI: 1–5%, I2 = 54%), respectively. In prespecified subgroup analyses of studies focusing on patients with intraparenchymal hemorrhage and/or CAA, pooled IRs for ischemic stroke, recurrent ICrH, and major hemorrhage IR of 4% (95% CI: 1–8%), 4% (95% CI: 0.4–10%) and 6% (95% CI: 3–12%), respectively.
Conclusions:
LAAO may be a safe and effective treatment for selected AF patients with a history of ICrH and/or CAA, but the quality of evidence is poor. Future randomized controlled trials are essential to validate LAAO’s efficacy and long-term safety.
Boston Area Anticoagulation Trial for Atrial Fibrillation I, SingerDEHughesRA, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New Engl J Med1990; 323: 1505–1511.
3.
HartRGPearceLAAguilarMI.Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med2007; 146: 857–867.
4.
van WalravenCHartRGSingerDE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA2002; 288: 2441–2448.
5.
Investigators SPiAF. Stroke prevention in atrial fibrillation study. Final results. Circulation1991; 84: 527–539.
6.
EzekowitzMDBridgersSLJamesKE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. New Engl J Med1992; 327: 1406–1412.
7.
Investigators SPiAF. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet1994; 343: 687–691.
8.
VermeerSEAlgraAFrankeCL, et al. Long-term prognosis after recovery from primary intracerebral hemorrhage. Neurology2002; 59: 205–209.
9.
WolfMEAlonsoAEbertADSzaboKChatzikonstantinouA.Etiologic and clinical characterization of patients with recurrent spontaneous intracerebral hemorrhage. Eur Neurol2016; 76: 295–301.
10.
CharidimouAShoamaneshAAl-Shahi SalmanR, et al. Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: The need for a balanced approach. Int J Stroke2018; 13: 117–120.
11.
KozbergMGPerosaVGurolMEvan VeluwSJ.A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke2021; 16: 356–369.
12.
EckmanMHRosandJKnudsenKASingerDEGreenbergSM.Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke2003; 34: 1710–1716.
13.
HolmesDRReddyVYTuriZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet (London, England)2009; 374: 534–542.
14.
ReddyVYDoshiSKSievertH, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation2013; 127: 720–729.
15.
ReddyVYSievertHHalperinJ, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA2014; 312: 1988–1998.
16.
HolmesDRJrKarSPriceMJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term Warfarin therapy: the PREVAIL trial. J Am Coll Cardiol2014; 64: 1–12.
17.
PouruJPLundJJaakkolaS, et al. Percutaneous left atrial appendage closure in patients with prior intracranial bleeding and thromboembolism. Heart Rhythm2020; 17: 915–921.
18.
AjmalMSipraQUARPecciCIqbalNRathoreS.Feasibility of left atrial appendage closure in atrial fibrillation patients with a history of intracranial bleeding: a systematic review of observational studies. J Interv Cardiol2020; 2020: 1575839.
19.
HaddawayNRPageMJPritchardCCMcGuinnessLA.PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev2022; 18: e1230.
20.
ClarkJGlasziouPDel MarCBannach-BrownAStehlikPScottAM.A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol2020; 121: 81–90.
21.
ClarkJMSandersSCarterM, et al. Improving the translation of search strategies using the Polyglot search translator: a randomized controlled trial. J Med Libr Assoc2020; 108: 195–207.
22.
OuzzaniMHammadyHFedorowiczZ, et al. Rayyan-a web and mobile app for systematic reviews. System Rev2016; 5: 210.
23.
SlimKNiniEForestierDKwiatkowskiFPanisYChipponiJ.Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg2003; 73: 712–716.
24.
AlsinbiliA.Assessing the risk of bias in single-arm trials for systematic reviews: moving towards a more reliable evaluation of clinical evidence. Future Healthc J2023; 10: 26–27.
25.
KhanWKhanMAlradwanHWilliamsRSimunovicNAyeniOR.Utility of intra-articular hip injections for femoroacetabular impingement: a systematic review. Orthop J Sports Med2015; 3: 2325967115601030.
26.
BalduzziSRückerGSchwarzerG.How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health2019; 22: 153–160.
27.
WanXWangWLiuJ, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol2014; 14: 135.
28.
VeronikiAAJacksonDViechtbauerW, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Method2016; 7: 55–79.
29.
ChenYChenDWangY, et al. Using freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Aesthetic Plastic Surg2023; 47: 83–84.
FletcherJ.What is heterogeneity and is it important?BMJ2007; 334: 94–96.
32.
HuckerWJCohenJAGurolME, et al. WATCHMAN implantation in patients with a history of atrial fibrillation and intracranial hemorrhage. J Interv Card Electrophysiol2020; 59: 415–421.
33.
Fayos-VidalFArzamendi-AizpuruaDMillán-ÁlvarezX, et al. Left atrial appendage closure in patients with intracranial haemorrhage and atrial fibrillation. Neurologia2020; 35: 10–15.
34.
FahmyPSpencerRTsangM, et al. Left atrial appendage closure for atrial fibrillation is safe and effective after intracranial or intraocular hemorrhage. Canad J Cardiol2016; 32: 349–354.
35.
CasuGD’AngeloGUgoF, et al. Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: a national multicenter study. Int J Cardiol2021; 328: 75–80.
36.
TzikasAFreixaXLlullL, et al. Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: results from the amplatzer cardiac plug registry. Int J Cardiol2017; 236: 232–236.
37.
HuttEWazniOMSalibaWI, et al. Left atrial appendage closure device implantation in patients with prior intracranial hemorrhage. Heart Rhythm2019; 16: 663–668.
38.
HorstmannSZugckCKrumsdorfU, et al. Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. Neurology2014; 82: 135–138.
39.
GilhoferTSNestelbergerTKangM, et al. Stroke prevention with left atrial appendage closure in patients with atrial fibrillation and prior intracranial hemorrhage. CJC Open2023; 5: 404–411.
40.
GalloFRoncoFD’AmicoG, et al. Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: Insights from the LOGIC (Left atrial appendage occlusion in patients with gastrointestinal or IntraCranial bleeding) International multicenter registry. Catheter Cardiovas Intervent2023; 101: 1144–1153.
41.
Cruz-GonzálezIRama-MerchanJCMartínez-PeraltaSLópez-MesoneroLRodríguez-ColladoJSánchezPL.Safety and effectiveness of percutaneous closure of left atrial appendage in patients with intracranial hemorrhage. Rev Esp Cardiol2017; 70: 58–60.
42.
BarocelliFColiSCrocamoA, et al. Left atrial appendage occlusion in patients with atrial fibrillation and large prevalence of prior intracranial bleeding. J Cardiovasc Med2020; 21: 583–591.
43.
AjmalMNaikHKocherilA.Left atrial appendage closure in patients with intracranial hemorrhage and nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis2020; 29: 104685.
44.
SchragMMac GroryBNackenoffA, et al. Left atrial appendage closure for patients with cerebral amyloid angiopathy and atrial fibrillation: the LAA-CAA cohort. Transl Stroke Res2021; 12: 259–265.
45.
RenouPThamboJBIriartX, et al. Left atrial appendage closure in patients with atrial fibrillation and previous intracerebral hemorrhage. J Stroke Cerebrovasc Dis2017; 26: 545–551.
46.
Nielsen-KudskJEJohnsenSPWesterP, et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. Eurointervention2017; 13: 371–378.
47.
Moliner-AbósCAlbertí-VallBMillan-ÁlvarezX, et al. Left atrial appendage occlusion in patients with spontaneous intracerebral hemorrhage: an observational study. J Stroke Cerebrovasc Dis2024; 33: 107481.
48.
BlancCBlancGBovedaS, et al. Left atrial appendage closure in patients with atrial fibrillation and coexisting cerebral amyloid angiopathy. Stroke2021; 52: e792–e793.
49.
FouksAAYaghiSGokcalE, et al. Left atrial appendage closure for patients with atrial fibrillation at high intracranial haemorrhagic risk. Stroke Vasc Neurol2024; 10: e003142.
50.
LinnJHalpinADemaerelP, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology2010; 74: 1346–1350.
51.
FreemanJVHigginsAYWangY, et al. Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol2022; 79: 1785–1798.
52.
FribergLRosenqvistMLipGY.Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J2012; 33: 1500–1510.
53.
GargJShahSShahK, et al. Left atrial appendage closure in patients with intracranial hemorrhage. J Intervent Cardiac Electrophys2022; 64: 551–556.
54.
SteinerT.Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke2011; 42: 3661–3662.
55.
TzikasAShakirSGafoorS, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. Eurointervention2016; 11: 1170–1179.
56.
HolmesDRDoshiSKKarS, et al. Left atrial appendage closure as an alternative to Warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol2015; 65: 2614–2623.
57.
ReddyVYMobius-WinklerSMillerMA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol2013; 61: 2551–2556.
58.
UrenaMRodes-CabauJFreixaX, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol2013; 62: 96–102.
59.
BoersmaLVInceHKischeS, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol2019; 12: e006841.
60.
HartRGDienerHCYangS, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke2012; 43: 1511–1517.
61.
GrangerCBAlexanderJHMcMurrayJJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med2011; 365: 981–992.
62.
PatelMRMahaffeyKWGargJ, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med2011; 365: 883–891.
63.
Archontakis-BarakakisPLiWKalaitzoglouD, et al. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: a systematic review and meta-analysis of 92 studies. Br J Clin Pharmacol2022; 88: 4663–4675.
64.
Archontakis-BarakakisPKokkinidisDGNagrajSGidwaniVMavridisTNtaiosG.Major hemorrhage risk associated with direct oral anticoagulants in non-valvular atrial fibrillation: a systematic review and meta-analysis. Rev Cardiovasc Med2022; 23: 334.
65.
Archontakis BarakakisPKokkinidisDGLiW, et al. Safety of direct oral anticoagulants for gastrointestinal hemorrhage in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of real-world studies. J Clin Gastroenterol2023; 57: 1045–1053.
66.
LiWJArchontakis-BarakakisPPalaiodimosL, et al. Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: an updated meta-analysis. World J Cardiol2021; 13: 82–94.
67.
SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol2021; 20: 842–853.
68.
SchreuderFHBMvan NieuwenhuizenKMHofmeijerJ, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol2021; 20: 907–916.
69.
ShoamaneshACommitteeE-AS. Anticoagulation in patients with cerebral amyloid angiopathy. Lancet2023; 402: 1418–1419.
70.
HindricksGPotparaTDagresN, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J2021; 42: 373–498.
71.
KlijnCJPaciaroniMBergeE, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J2019; 4: 198–223.
72.
WilsonDAmblerGLeeKJ, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol2019; 18: 653–665.
73.
Van GelderICRienstraMBuntingKV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2024; 45: 3314–3414.
74.
BoersmaLVInceHKischeS, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm2017; 14: 1302–1308.
75.
ReddyVYDoshiSKKarS, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol2017; 70: 2964–2975.
Avoiding Anticoagulation After IntraCerebral Haemorrhage. Ministry of Health and L’Institut national de la santé et de la recherche médicale, 2017, https://clinicaltrials.gov/study/NCT03243175
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
